Incyte received a stock rating upgrade and price target increase from an unnamed source, involving Wells Fargo.
1 report, 1 independent
Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Incyte received a stock rating upgrade and price target increase from an unnamed source, involving Wells Fargo.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Incyte
American pharmaceutical company
-
Wells Fargo
American multinational banking and financial services company
Related events
- Wells Fargo raised a price target to $56, while Goldman Sachs research highlighted risks associated with AI agents.
- Morgan Stanley upgraded Wells Fargo's rating, and TD Cowen began coverage on the company.
- Wells Fargo raised its price target for Meta on October 7, 2026.
- Benchmark and Wells Fargo maintained or reiterated positive investment ratings on Teck Resources in August 2025.
- Wells Fargo downgraded the price target for RPM International, citing a cautious outlook.
Coverage
Newest first; wire copies grouped- Insider MonkeyWells Fargo Upgrades Incyte Corporation (INCY) to Overweight From Equal Weight Incyte Corporation (NASDAQ:INCY) is one of the top most undervalued biotech stocks to buy now. Wells Fargo upgraded Incy